The global biopharmaceutical industry witnessed multiple groundbreaking developments over the past weekend and as of the morning of September 14, 2026. As the 2026 World Conference on Lung Cancer (WCLC) convened in Seoul, a Chinese-developed bispecific antibody demonstrated a statistically significant overall survival (OS) advantage over Keytruda in a head-to-head trial, reshaping the paradigm for … Chinese Bispecific Antibody Tops Keytruda in First Head-to-Head OS Win; SMA Muscle-Strengthening Therapy Approved, B7-H3 ADC Shows Promise Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.